Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23186699 | 0.81 | GAA (0.49) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL20411116 | 0.80 | MC4R (0.49) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL20411117 | 0.78 | GAA (0.46) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL20411087 | 0.78 | GAA (0.46) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL20402656 | 0.78 | GAA (0.46) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL20402657 | 0.78 | GAA (0.46) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL20397168 | 0.78 | GAA (0.46) | GAAMEN1TSHRKMT2AFUCA1 | |
| SCHEMBL15939000 | 0.78 | GAA (0.44) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL4482745 | 0.78 | FUCA1 (0.46) | GAAMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL3988127 | 0.78 | SIGMAR1 (0.43) | GAASIGMAR1FUCA1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| CN-113149968-B | Compound serving as ketohexokinase inhibitor and application thereof | 博济医药科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | GAA 1523/4885MEN1 1950/4885TSHR 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.